Vitrolife Group

What Vitrolife Group does

Vitrolife Group (Vitrolife AB (publ)) is a Swedish-headquartered, NASDAQ Stockholm Large Cap-listed provider of medical devices, consumables, and genetic testing services for the global IVF market. Operating through two main brands — Vitrolife (consumables and technologies) and Igenomix (reproductive genetic testing) — the group sells oocyte retrieval needles, cryopreservation devices, transfer media, the EmbryoScope time-lapse incubation system with the proprietary iDAScore AI embryo-evaluation model, laser technology, and the eWitness/eBase clinic management software acquired with eFertility in May 2024. Igenomix contributes a portfolio of reproductive genetic tests including the pioneering Endometrial Receptivity Analysis (ERA), PGT, and a non-invasive PGT approach using cell-free DNA in embryo culture medium.

The group serves IVF clinics and reproductive-health professionals (clinicians, embryologists, genetic counsellors) in more than 25 countries, with priority growth markets in the US, Europe, Japan and Asia-Pacific. Revenue is generated through three streams: medical device and consumables sales to IVF clinics (hardware/consumables revenue), genetic testing services via Igenomix (professional services revenue), and increasingly software/SaaS-style digital clinic management through eWitness/eBase (subscription/recurring revenue). Pricing is quote-based through a direct global sales force with regional SVP/MD leadership, supported by the Vitrolife Group Academy for clinician training and enablement, and brand-dedicated websites (vitrolife.com and igenomix.eu). The company employs around 1,150 colleagues and is incorporated in Gothenburg, Sweden under Vitrolife Aktiebolag (publ), with Igenomix (Spain) and eFertility as wholly-owned operating subsidiaries.

Recent strategic posture is defensive and consolidating. A December 2025 genetic services restructuring (targeting SEK 65M annualised savings, discontinuing two test lines and exiting low-profit markets) accompanied a SEK 5.4 billion goodwill impairment related to the Igenomix acquisition in Q4 2025. The CEO Bronwyn Brophy O'Connor announced her departure on 22 May 2026, while a new COO (Olivier Desmarets) was appointed 1 June 2026 to lead global Manufacturing, Labs, Supply Chain, Quality and Customer Care. The company is listed (ticker VITR; ISIN SE0011205202) with major shareholders including William Demant Invest A/S, Bure Equity AB, and AMF Fonder & Pension represented on the Nomination Committee.

Name

Vitrolife Group

Legal name

Vitrolife Aktiebolag (publ)

Website

https://vitrolifegroup.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Vitrolife Group is a Swedish-listed global provider of IVF medical devices, consumables, and reproductive genetic testing. Through its Vitrolife and Igenomix brands, it serves IVF clinics and reproductive-health professionals in over 25 countries with consumables, the EmbryoScope/iDAScore AI embryo-evaluation platform, and genetic tests such as ERA and non-invasive PGT.

Ownership category

akta.pro rank

Product category

Reproductive Health Medical Devices & Genetic Testing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

akta.pro secondary industries

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• IVF consumables
• Reproductive genetic testing
• Embryo time-lapse incubation
• Fertility medical devices
• IVF clinic management software

Headquarters

HQ city

Västra Frölunda

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical device and consumables sales: Sale of Vitrolife-branded IVF consumables (oocyte retrieval needles, cryopreservation devices, transfer media) and Technologies (time-lapse systems, laser, witnessing) to IVF clinics globally.
2. Genetic testing services: Sale of Igenomix genetic tests (e.g., ERA, PGT-A, non-invasive PGT) to reproductive-health professionals across the reproductive journey.
3. IVF clinic management software (eWitness / eBase): Software/SaaS-style digital clinic management and electronic witnessing for IVF workflows, acquired via eFertility (EUR 1.5 million revenue in 2023).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Vitrolife Group is a global provider of medical devices, technologies, and genetic testing solutions for the IVF and reproductive-health journey. Its portfolio spans Consumables (oocyte retrieval needles, cryopreservation devices, transfer media), Technologies (EmbryoScope time-lapse incubation, laser technology, AI-based embryo evaluation via iDAScore, eWitness witnessing systems), and Genetic Services delivered under the Igenomix brand (Endometrial Receptivity Analysis, PGT, non-invasive PGT via cell-free DNA). It also sells IVF clinic management software (eBase) acquired via eFertility.

Product overview

Vitrolife Group operates a platform-plus-modules architecture organized under two primary brands: Vitrolife (medical devices and clinic software for IVF) and Igenomix (genetic testing services for reproductive health). The Vitrolife brand is structured into Consumables (oocyte retrieval needles, cryopreservation devices, transfer media), Technologies (the EmbryoScope time-lapse system, laser technology, and the witnessing system eWitness acquired via eFertility), and the broader IVF workflow suite that includes the eBase clinic management platform. Igenomix provides the genetic services portfolio (including the ERA endometrial receptivity analysis) covering pre-, during-, and post-reproductive stages. AI capability is delivered through the in-house iDAScore model that sits on top of EmbryoScope time-lapse imagery, and the group has expanded into adjacent automated IVF technology via its investment in AutoIVF and its OvaReady product.

Differentiator

Problem solved

Functional benefit

Brands

• Vitrolife: Brand of innovative, high-quality IVF journey products including oocyte retrieval needles, cryopreservation devices, transfer media, pioneering time-lapse and laser technology, and the latest witnessing system.
• Igenomix

Products and services

• Vitrolife Consumables

Quantifiable outcome

• 5% organic growth in local currencies in Q1 2026 with strong growth in Consumables and Technologies
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered major / strategic acquisition target, transformational acquisition, operational / compliance, statutory auditor (high importance for governance), key opinion leader / scientific partner, key opinion leader in japan, key opinion leader / clinic chain partner and key opinion leader in the us.

• eFertilitymajor / strategic acquisition targetStrategic or Co-development Partner · 2 May 2024Vitrolife signed an agreement to acquire all shares of eFertility for EUR 9.6 million plus potential earn-out, completed on 22 May 2024. The deal brought eFertility's eWitness and eBase IVF clinic management systems into Vitrolife Group, supporting its strategy to digitalise and standardise IVF workflows worldwide. eFertility contributed EUR 1.5 million in revenues in 2023.
• Igenomix S.L. (acquired via Mendel Holdco S.L.)transformational acquisitionStrategic or Co-development Partner · 8 July 2021Vitrolife acquired all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L. in 2021 via a directed share issue, increasing share count by 17,251,312 (12.7% dilution) and share capital by SEK 3,519,267.648. Igenomix is now a core brand within Vitrolife Group's Genetic Services portfolio.
• WhistleB / NAVEX (whistleblowing service provider)operational / complianceTechnology or IntegrationExternal partner providing Vitrolife Group's anonymous and encrypted whistleblowing service (report.whistleb.com/en/vitrolife), administered by WhistleB Whistleblowing Centre AB (Stockholm). Handles criminal offences, financial irregularities, health & safety, environmental and privacy violations.
• Deloitte ABstatutory auditor (high importance for governance)Implementation/ SI/ Consulting PartnerDeloitte AB was re-elected at the 2026 AGM as Vitrolife's statutory auditor for one year, with Anneli Pihl (authorised public accountant) as auditor in charge. Office: Södra Hamngatan 53, Box 33, SE-401 20 Göteborg.
• Melbourne IVF / Virtus Health (David K. Gardner)key opinion leader / scientific partnerStrategic or Co-development PartnerScientific collaboration with David K. Gardner, Scientific Director of Melbourne IVF, a pioneer of blastocyst culture and the 'Gardner Grade' embryo grading system. He contributed to the Capital Markets Day 2023 on IVF history and future.
• Kato Ladies Clinic (Keiichi Kato, M.D.)key opinion leader in japanStrategic or Co-development PartnerClinical perspective partner; Dr. Keiichi Kato, General Director of Kato Ladies Clinic (Tokyo), participates in Vitrolife's CMD 2023 panel on IVF market dynamics in Japan and natural/minimal stimulation IVF.
• Eugin Group (Eduardo Gonzalez)key opinion leader / clinic chain partnerStrategic or Co-development PartnerClinical perspective partner; Eduardo Gonzalez, Group CEO of Eugin Group (a reproductive-health clinic chain headquartered in Barcelona, Spain), contributes to the CMD 2023 panel on European IVF market dynamics.
• UCSF Center for Reproductive Health (Mitchell Rosen, M.D.)key opinion leader in the usStrategic or Co-development PartnerClinical perspective partner; Dr. Mitchell Rosen of UCSF participates in CMD 2023 panels on IVF market dynamics and clinical experience using EmbryoScope.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• FUJIFILM Irvine Scientific: A leading global supplier of IVF culture media, cryopreservation solutions, and ART devices, directly competing with Vitrolife's Consumables portfolio. Its media franchise is the closest substitute to Vitrolife's transfer media and cryopreservation products used by the same IVF clinics.
• Natera: Natera's Spectrum PGT-A and Empower hereditary cancer test compete head-on with Igenomix's PGT-A and reproductive genetics offering. Both target the same IVF-clinic channel for preimplantation and reproductive genetic testing decisions.
• Kitazato Corporation: Kitazato is a leading Japanese provider of IVF consumables, cryopreservation devices (Cryotop), and culture media, competing directly with Vitrolife Consumables across Asia-Pacific and globally, particularly in Japan - one of Vitrolife's stated priority markets.
• Genea Biomedx: Genea Biomedx (part of Genea World) supplies IVF lab equipment including the Geri time-lapse incubator and Gems culture media, directly competing with Vitrolife's EmbryoScope time-lapse system and Consumables media range. Both target the same IVF lab purchasing decision.
• Hamilton Thorne: Hamilton Thorne manufactures time-lapse embryo incubators (e.g., Gery and recently acquired LYKOS) and IVF lab equipment, directly competing with Vitrolife's EmbryoScope and Technologies product lines. Its laser and micromanipulator products further overlap Vitrolife's Technologies portfolio.
• CooperGenomics (Preimplantation Genetics): CooperGenomics provides PGT-A, PGT-M, and PGT-SR genetic testing services to IVF clinics, directly overlapping with Igenomix's PGT portfolio. Both serve the same reproductive-health professional customer with comparable chromosomal and monogenic disease screening tests.

Broad incumbents

• CooperSurgical (CooperCompanies): CooperSurgical's Fertility and Genomic Solutions business directly overlaps with Vitrolife's IVF consumables, genetic testing (PGT-A), and genomics portfolio. As part of a diversified medical-device conglomerate, it competes across multiple layers of the IVF stack but does not match Vitrolife's full end-to-end integration with EmbryoScope/iDAScore.
• Merck KGaA (Life Science / Sigma-Aldrich IVF): Merck supplies IVF/ART media, cryopreservation reagents, and bench research products used by fertility clinics and embryologists, overlapping with Vitrolife Consumables. As a large diversified science conglomerate it competes on breadth rather than Vitrolife's specialty IVF focus.

Regional players

• Progyny: Progyny is a US fertility benefits management company that partners with employers to offer IVF coverage, indirectly influencing demand for Vitrolife's products. While not a direct product competitor, it shapes US purchasing power for the same IVF clinics and could serve as a channel or partnership target for Vitrolife's US push.

Emerging players

• AIVF: AIVF is an Israel-based emerging IVF technology company developing AI-driven embryo evaluation software (EMMA, DALIA), directly competing with Vitrolife's iDAScore AI embryo-scoring model. It represents a focused, well-funded entrant into AI embryo selection that could pressure iDAScore's pricing power.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vitrolife-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitrolife Group